Category - Developments

Developments

Precigen receives FDA breakthrough nod for AdenoVerse in RRP

The FDA granted breakthrough therapy designation for Precigen’s (NASDAQ:PGEN) investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis (RRP). Standard-of-care for RRP...

June 20, 2023

Developments

Rhythm presents BMI reduction data in hypothalamic obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) presented data that showed meaningful weight loss was sustained and progressed in patients with hypothalamic obesity treated with its setmelanotide for six months as part of the long...

June 19, 2023

Developments

Hepion to present 2 posters at EASL International Liver Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) will present two abstracts for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 taking place June 21 – 24 in...

June 16, 2023

Developments

Hepion Phase 2b ASCEND-NASH trial passes key safety milestone

A data and safety monitoring board (DSMB) has reviewed the current data for Hepion Pharmaceuticals’ (NASDAQ:HEPA) ASCEND-NASH Phase 2b trial with rencofilstat and issued a “study may proceed without modification”...

June 15, 2023

Developments

2seventy’s CAR-T trial halted after pediatric death

2seventy bio’s (NASDAQ:TSVT) partner, Seattle Children’s Hospital, paused a Phase 1 CAR T-cell therapy trial for pediatric acute myeloid leukemia after a patient death. The child was the first to receive the second dose...

June 15, 2023

Developments

Zucara receives additional JDRF funding for Phase 2 study

Closely held Zucara Therapeutics received an additional $2-million in funding from JDRF (Juvenile Diabetes Research Foundation) to support Zucara’s planned Phase 2a study of the effect of its ZT-01 on nocturnal...

June 15, 2023

Developments

Confo, AbCellera in GPCR-targeting antibody discovery program

Confo Therapeutics of Belgium entered into a research collaboration with AbCellera Biologics (NASDAQ:ABCL) for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets (G protein-coupled...

June 15, 2023

Developments

Blue Water acquires 6 FDA-approve drugs across various indication

Blue Water Biotech (NASDAQ:BWV) signed asset purchase agreements with WraSer and Xspire Pharma to acquire six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management...

June 14, 2023

Developments

Annovis Bio completes enrollment in Phase 3 Parkinson’s trial

Annovis Bio’s (NYSE:ANVS) Parkinson’s disease (PD) Phase 3 clinical trial of its lead compound, buntanetap, reached full enrollment in a record nine months after it began. Since the first patient was dosed in late...

June 8, 2023

Developments

FibroGen flunks Phase 3 in non-ambulatory DMD

FibroGen’s (NASDAQ: FGEN) Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD) on background corticosteroids did not meet the...

June 8, 2023

Category - Developments

Subscribe